This bill matters because it directly impacts the balance between making prescription drugs affordable for seniors and encouraging the development of new, life-saving medicines. If this bill becomes law, certain innovative drugs from smaller biotech firms won't be subject to Medicare's price negotiation rules, which could mean these drugs remain more expensive for Medicare and potentially for beneficiaries through co-pays or premiums. However, this higher price might also give these small companies more funds and incentive to keep researching and bringing new treatments to market, especially for rare diseases or unmet medical needs.
If the bill doesn't pass, all qualifying drugs, including those from small R&D-intensive biotech companies, would eventually be subject to Medicare price negotiations. This could lead to lower drug costs for Medicare, but some argue it might reduce the financial incentive for small biotech companies to take risks on developing new drugs, especially those with smaller markets or longer development times. It's a debate about how best to foster medical innovation while managing healthcare costs.
KEY PROVISIONS
5AI-extracted
PROVISION 01
Establishes an exception for "research and development-intensive small biotech manufacturers" from the Medicare drug price negotiation program, beginning in 2029.
This provision aims to protect certain small biotech companies from price negotiations, potentially fostering innovation.
PROVISION 02
Defines a "small biotech manufacturer" as a company with 5 or fewer qualifying single-source drugs, not owned or controlled by certain foreign governments.
This sets clear criteria for which companies can potentially qualify for the exception, targeting smaller, independent innovators.
PROVISION 03
Defines a "research and development-intensive small biotech manufacturer" as one that invests a specific percentage (ranging from 30% to 70% based on number of drugs) of its net revenue in R&D.
This ensures the exception primarily benefits companies genuinely focused on drug discovery and development.
PROVISION 04
Specifies that a drug loses the exception if the manufacturer is acquired after 2029 by a company that does not meet the R&D-intensive small biotech manufacturer definition.
This prevents larger companies from acquiring small biotech firms solely to exploit the exception, ensuring its benefits stay with truly small innovators.
PROVISION 05
Requires annual applications from manufacturers to the Secretary of Health and Human Services to prove eligibility for the exception and establishes a dispute resolution process.
This provides a mechanism for oversight and allows manufacturers to challenge adverse determinations regarding their eligibility.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill matters because it directly impacts the balance between making prescription drugs affordable for seniors and encouraging the development of new, life-saving medicines. If this bill becomes law, certain innovative drugs from smaller biotech firms won't be subject to Medicare's price negotiation rules, which could mean these drugs remain more expensive for Medicare and potentially for beneficiaries through co-pays or premiums. However, this higher price might also give these small companies more funds and incentive to keep researching and bringing new treatments to market, especially for rare diseases or unmet medical needs.
If the bill doesn't pass, all qualifying drugs, including those from small R&D-intensive biotech companies, would eventually be subject to Medicare price negotiations. This could lead to lower drug costs for Medicare, but some argue it might reduce the financial incentive for small biotech companies to take risks on developing new drugs, especially those with smaller markets or longer development times. It's a debate about how best to foster medical innovation while managing healthcare costs.
KEY PROVISIONS
AI-extracted
high
Establishes an exception for "research and development-intensive small biotech manufacturers" from the Medicare drug price negotiation program, beginning in 2029.
This provision aims to protect certain small biotech companies from price negotiations, potentially fostering innovation.
high
Defines a "small biotech manufacturer" as a company with 5 or fewer qualifying single-source drugs, not owned or controlled by certain foreign governments.
This sets clear criteria for which companies can potentially qualify for the exception, targeting smaller, independent innovators.
high
Defines a "research and development-intensive small biotech manufacturer" as one that invests a specific percentage (ranging from 30% to 70% based on number of drugs) of its net revenue in R&D.
This ensures the exception primarily benefits companies genuinely focused on drug discovery and development.
med
Specifies that a drug loses the exception if the manufacturer is acquired after 2029 by a company that does not meet the R&D-intensive small biotech manufacturer definition.
This prevents larger companies from acquiring small biotech firms solely to exploit the exception, ensuring its benefits stay with truly small innovators.
med
Requires annual applications from manufacturers to the Secretary of Health and Human Services to prove eligibility for the exception and establishes a dispute resolution process.
This provides a mechanism for oversight and allows manufacturers to challenge adverse determinations regarding their eligibility.
Exception begins for initial price applicability year
Not specified, but tied to an annual process
Dispute resolution process must conclude by the selected drug publication date for the initial price applicability year for which the manufacturer submitted an application.
GLOSSARY
AI-written
Medicare drug price negotiation program
A program under Medicare that allows the government to negotiate lower prices for certain high-cost prescription drugs, aiming to reduce costs for beneficiaries and the program.
Qualifying single source drug
A prescription drug that is approved by the FDA, does not have generic or biosimilar competition, and meets other specific criteria making it eligible for Medicare's price negotiation program.
Small biotech manufacturer
A company that produces biological drugs (often complex medicines), has five or fewer qualifying unique drugs, and is not owned or controlled by certain foreign governments.
Research and development-intensive small biotech manufacturer
A small biotech manufacturer that invests a significant percentage (between 30% and 70%, depending on its number of drugs) of its recent income back into creating new medicines and scientific discovery.
Initial price applicability year
The first year that a specific negotiated drug price goes into effect for a particular drug under the Medicare drug price negotiation program.
Net revenue
The total income a company receives from sales after subtracting returns, allowances, and other direct sales-related deductions, over a specific period.
ACTION TIMELINE
2 EVENTS
JUN 4, 25
Introduced in House
INTROREFERRAL
JUN 4, 25
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The date by which the Secretary of Health and Human Services must publish the list of drugs selected for price negotiation under the Medicare program for a given year.
